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ABSTRACT 
Between November 1987 and September 1989, 419 cadaveric renal transplants were performed at 
our university. Of the patients 36 (8.6%) had invasive cytomegalovirus infection documented by 
gastric or duodenal mucosal biopsy in 23 (64%), bronchoalveolar lavage in 12 (33%), allograft biopsy 
or nephrectomy specimen in 5 (14%) and/or liver biopsy in 1 (3%). Cytomegalovirus severity was 
defined as mild in 27 patients, moderate in 6 and severe in 3. Ganciclovir [9-(1,3-dihydroxY-2-
propoxymethyl)-guanine J was begun once the diagnosis was confirmed by histology or culture at a 
median of 56 days from transplantation (range 28 to 133 days). Duration of ganciclovir therapy was 
a minimum of 7 days or until fever was absent for 5 consecutive days (mean 12.2 ± 3.5 days, range 
4 to 21). Ganciclovir was well tolerated and side effects were limited to de novo neutropenia (7 
patients), thrombocytopenia (2) and rash (1). Initial clinical improvement was observed in all 
patients. Two patients had recurrent cytomegalovirus infections that responded to a second course 
of ganciclovir. The I-year actuarial patient survival was 100%. At a mean followup of 12.7 ± 6.2 
months 19 patients retained allograft function with a mean serum creatinine of 2.5 mg./dl. (range 
1.2 to 4.6). Ganciclovir appears to be a safe and effective drug for the treatment of tissue invasive 
cytomegalovirus infection in cadaver renal transplant recipients. Prompt institution of this drug at 
diagnosis of invasive cytomegalovirus may lower the mortality rate formerly associated with this 
disease. 
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Renal transplant recipients with tissue invasive cytomeg-
alovirus infection have had as much as a 25% risk of dying, 
even when immunosuppression is decreased or stopped. \ Until 
recently, there was no effective therapy for this group of pa-
tients. Ganciclovir [9-(1,3-dihydroxy-2-propoxymethyl)-guan-
ine I is metabolized by viral kinases within infected host cells 
to yield 2' ·nor-2'deoxyguanine, a potent inhibitor of herpes-
virus deoxyribonucleic acid polymerase.2 Although previous 
studies have reported its usefulness for life or sight-threatening 
cytomegalovirus infections in immunocompromised hosts. l . w 
the optimum use of ganciclovir in cadaver renal transplant 
recipients with tissue invasive cytomegalovirus has not yet been 
established. We report our experience with the use of ganciclo-
vir in treating tissue invasive cytomegalovirus infection follow· 
ing cadaver renal transplantation. The results suggest that this 
drug is well tolerated and is effective in arresting the progress 
of invasive cytomegalovirus to life-threatening disease with 
little or no drug-related morbidity. 
MATERIALS AND METHODS 
Patients. Of 419 cadaveric renal allograft recipients who 
underwent transplantation at our university between Novem-
ber 1987 and September 1989, 36 (8.6%) had tissue invasive 
cytomegalovirus infection, including 25 men and 11 women 
(mean age 42.1 ± 11.5 years, range 18 to 71). Cytomegalovirus 
serology was determined by solid phase fluorescence immu-
noassay of IgG antibodies to cytomegalovirus. Immunoassay 
titers of less than 20 were considered negative, 20 to 30 equiv-
ocal and more than 30 seropositive. In 16 of the 36 patients 
Accepted for publication April 3. 1992. 
Read at annual meeting of American Urological Association. To-
ronto. Ontario, Canada. June :2-6. 1991. 
(44 %) an allograft from a cytomegalovirus seropositive donor 
was transplanted into a seronegative recipient. Nine CIUlel 
(25%) were seropositive to seropositive, 5 (14%) were seroneg. 
ative to seropositive and 4 (11 %) were seronegative to seroneg. 
ative. Cytomegalovirus serology was not available from 2 do. 
nors. Prophylactic acyclovir was given to all patients at either 
low dose (200 mg. twice daily in 28) or high dose (up to 3,200 
mg./24 hours based on renal function in 8). L \ 
Immurwsuppression. A standard immunosuppressive regi. 
men including cyclosporine (15 to 17.5 mg./kg. orally before 
transplantation, subsequently tapered to maintain whole blood 
high performance liquid chromatography levels of 100 to 200 
ng./ml.), prednisone (tapered to 0.1 mg./kg. by 3 months) and 
azathioprine (3 to 5 mg./kg. preoperatively tapered by 1 mg.; 
kg. per day to a maintenance dose of 1 mg./kg. per day) was 
used in all patients. A total of 8 patients (22%) received 
prophylactic OKT3 (5 mg, daily for 10 to 14 days). Rejection 
episodes were defined clinically by an increase in serum creat· 
inine accompanied by fever, decreased urinary output, graft 
tenderness and/or weight increase and were confirmed by a 
core needle biopsy. Rejection was treated with increased steroid 
therapy and/or a 10 to 14-day course of OKT3. 
Definitwns of cytomegalovirus infection, Cytomegalovirus in-
fection was clinically suspected in patients with unexplained 
fever 38.3C or greater for more than 2 days, leukopenia (white 
blood count less than 4,OOO/mm.:l), thrombocytopenia (platelet 
count less than 100,OOO/mm. J ) and/or diffuse pulmonary infil-
trates. Cultures of blood, urine and pharyngeal washings were 
performed in all patients. When clinically indicated. the pres' 
ence of tissue invasive cytomegalovirus was sought by bron· 
choalveolar lavage, upper gastrointestinal endoscopy with bi· 
opsy, liver biopsy, lumbar puncture, bone marrow examination 
and/or renal allograft biopsy. The diagnosis of tissue invasive 
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cytomegalovirus required histological documentation of cyto-
megalic inclusion bodies and/or positive tissue cultures for 
cytomegalovirus. An increase in serum antibody titer and/or 
seroconversion was considered insufficient for the diagnosis of 
tissue invasive cytomegalovirus. Only those patients with in-
vasive cytomegalovirus infection as defined by these criteria 
were considered as candidates for therapy with ganciclovir. 
Categories of cytomegalovirus severity. Disease severity was 
based on 6 clinical features defined previously by Peterson et 
al: 1) prolonged fever (temperature 38.3C or greater for more 
than 7 days), 2) diffuse pulmonary infiltrates, 3) gastrointes-
tinal bleeding. 4) pancreatitis. 5) transplant nephrectomy and 
6) development of another systemic infection.' Patients with 
severe cytomegalovirus infection had at least 3 of these 6 
features, patients with moderate disease had 2 of these features 
and mild cytomegalovirus disease was defined by the presence 
of no more than 1 of these features. 
Ganciclovir therapy. Ganciclovir was made available with 
mformed consent to patients with proved tissue invasive cyto-
megalovirus on a compassionate release basis. The protocol 
was approved by the local Institutional Review Board. Imme-
diately after the diagnosis of tissue invasive cytOmegalovirus 
was established, ganciclovir was administered intravenously at 
2.5 mg./kg. every 12 hours if the calculated creatinine clearance 
was more than 50 ml. per minute, 2.5 mg./kg. every 24 hours 
lor a creatinine clearance of 25 to 50 ml. per minute and 1.25 
mg./kg. every 24 hours for a creatinine clearance of less than 
25 mi. per minute. Hemodialysis patients received 1.25 mg./kg. 
after each dialysis and every 24 hours. Patients on peritoneal 
dialysis were given 1.25 mg./kg. every 48 hours. Treatment 
lasted for a minimum of 7 days and was continued until the 
patient was afebrile for 5 consecutive days. Duration of ganci· 
(lovir therapy was extended if persistent symptoms or evidence 
of widely disseminated infection were present. Baseline and 
-torial complete blood counts, serum electrolyte determinations 
,Ind renal function tests were performed daily in all patients. 
1.lver function tests were done twice weekly or daily for patients 
"'1th hepatitis. End points used to evaluate the outcome of 
n1omegalovirus infection included patient survival, resolution 
?f clinical symptoms, reversal of chest radiographic, hemato-
l<lllC and liver function abnormalities, and elimination of the 
~frua from the affected tissue or body fluid as determined 
'Ktopathologically or by culture. 
StatIStical analysis. Actuarial patient and graft survival rates 
'-"'re determined bv life-table analvsis using BMDP statistical 
.. )ft_are. Potential risk factors we~e studied for their effects on 
"1ornegalovirus severitv and treatment outcome and were 
(Ylm .... ·red b" , 
... Y chi-square analysis. 
RESULTS 
.f 1~l4onopis o[ tissue invasive c:vtomegalovirus infection. A total 
!1Ofl ~t1ents with clinically suspected cytomegalovirus infec-
D~ tissue Invasive cvtomegalovirus a mean of 60.6 davs 
.... DsI~n 55.8, range 28 to i33) after transplantation. Cytome'g-
;'; .. In.dl infection was clinically suspected because of unex-~flrnlll fever In P~ patients (89% 1. leukopenia in 21 (58%), !~ .. bocYtopema m 6 (17%) and/or diffuse pulmonary infil· 
'-t III In 9 (25C:;'1. Of the patients 27 (75%) had mild, 6 (l7c,c) 
.... ~erate ~nd 3 (8%) had severe infection (table 1). There 
~ ethallnfections. The pattern of cytomegalovirus tissue 
;~ I rent was stomach/duodenal mucosa in 26 patients 
-D~ftf~1 ung III 14 (39%), allograft in 5 (14), liver in 1 (3%) and 
I." f'Yto' Bites In 11 (31 %). Biopsies were considered positive 
~1C~egalovlrus based on viral culture or histology/immu-
~ biood°PY. Tissue diagnosis was accompanied by positive 
; t~~1 'rid c~ltures in 17 patients (46se I, urine cultures in 19 
~K l~F unC: aryngeal washmgs III 2 (sse l. A total of 8 patients -'lIIIoph rwent treatment for concurrent infections, includ-
. -",; ageal or gastric candidiasis 14), Pneumocystis carinii 
pneumonia (1), pseudomonal pneumonia (1), pseudomonal al-
lograft pyelonephritis (1) and Escherichia coli urosepsis (1). 
Management of immunosuppression during cytomegalovirus 
infection. Azathioprine was discontinued or temporarily with-
held in 31 patients, decreased in 4 and continued without 
change in dosage in 1 following the diagnosis of cytomegalovirus 
infection. Cyclosporine was stopped in 6 patients with non-
functioning allografts at cytomegalovirus diagnosis. In the re-
mainder cyclosporine was either temporarily withheld (6, mean 
7 days) or continued with (4) or without (20) dosage reduction. 
Prednisone dosage was lowered in 23 patients and continued 
without change in the remaining 13. 
Outcome of ganciclovir therapy. A total of 36 patients with 
documented tissue invasive cytomegalovirus infection was 
treated for 12.2 ± 3.5 days (range 4 to 21) and followed for an 
average of 12.7 months. One patient refused further therapy 
after 4 days but showed no evidence of residual or recurrent 
disease. Ganciclovir was well tolerated by all 36 patients. Side 
effects were limited to transient, de novo leukopenia (white 
blood count less than 4,000) in 7 patients, thrombocytopenia 
(less than 100,000) in 2 and rash in 1, none of whom required 
discontinuation of the drug. Serum creatinine was unaltered by 
ganciclovir in patients with functioning grafts (mean 4.1 ± 1.6 
mg./dl. before and 3.8 ± 1.9 after gancic10vir therapy). Follow-
ing the initial course of treatment with ganciclovir, all 36 
patients had complete resolution of symptoms (fever, fatigue, 
malaise, cough and abdominal discomfort) associated with cyto-
megalovirus. A total of 18 patients had positive baseline cul-
tures for cytomegalovirus from at least 1 body fluid with at 
least 1 followup culture after ganciclovir treatment. The figure 
summarizes the virological data of these patients before and 
after ganciclovir therapy. The overall virological responses for 
patients with initial viremia and/or viruria are summarized in 
table 2. Viral blood cultures were negative 7.5 ± 3.6 days after 
starting ganciclovir in 11 of 11 patients (100%) who had positive 
blood cultures before therapy. Of the 13 patients with initially 
positive urine cultures 11 (85%) became negative at 8.1 ± 4.8 
days and 2 remained positive. All 9 patients with initially 
positive cultures for blood and urine were cleared after ganci-
clovir. Tissue sampling was repeated in 7 patients after ganci-
c10vir therapy. In 1 patient with cytomegalovirus pneumonia 
repeat bronchoalveolar lavage was negative for cytomegalovirus 
68 days after ganciclovir. Two stomach biopsies were rendered 
negative 8.0 ± 9.9 days after treatment and 4 duodenal biopsies 
were negative at 29.3 ± 20.9 days. 
Factors potentially influencing cytomegalovirus severity and 
outcome. There was no correlation between cytomegalovirus 
severity and recipient age (more than 45 or 45 or less years), 
interval to cytomegalovirus onset after transplantation, prior 
rejection, OKT3 use, use of low dose versus high dose prophy-
lactic acyclovir, or donor/recipient cytomegalovirus serology 
status (table 3), Graft survival, however. was higher in inverse 
proportion to disease severity, with 17 of 27 grafts (63%) still 
functioning in patients originally having mild, 3 of 6 (50%) in 
those with moderate and 0 of 3 (0%) in those with severe 
disease (p <0.021. 
Graft losses. There was a total of 17 graft losses in this series: 
4 were lost at the onset of cytomegalovirus infection (primary 
graft nonfunction in 2 and chronic rejection in 2). The remain· 
ing 13 graft losses occurred at a median of 5 weeks (range 10 
days to 16 months) following invasive cytomegalovirus infec-
tion. One patient underwent allograft nephrectomy after im-
munosuppression was withheld for transverse mvelitis 2 
months after treatment with ganciciovir. Concurrently, he had 
benign cerebrospinal fluid and no evidence of ongoing cyto-
megalovirus infection. One patient lost the graft to rejection 
concurrent with acute pancreatitis (with negative cytomeg-
alovirus evaluation) 2 months after treatment, and 1 patient 
had recurrent oxalosis and graft failure 1 year after ganciciovir. 
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Results of viral cultures for cytomegalovirus before, during and after 
ganciclovir therapy. Patients 10 and 30 had asymptomatic urinary 
,;hedding, which was not treated. Patient 27 had recurrent cytomeg-
alovirus in allograft 60 days after initial treatment and was successfully 
retreated with 14-day course of ganciclovir. Patient :!9 had recurrent 
.:ytomegalovlrus gastrItis at 50 days. which was successfully retreated 
with 19-day course of gancic1ovir. 
Two patients had primary graft nonfunction and the remaining 
8 grafts were lost to rejection. 
Cytomegalovirus and rejection episodes. A total of 29 patients 
(81 or,) with invasive cytomegalovirus infections had been pre-
viously treated for rejection with either increased steroid ther-
apy alone in 18 (50%), OKT3 (5 mg. daily for 10 days) alone in 
:2 (6%), or OKT3 and steroids in 9 (25%). Prophylactic OKT3 
was used in an additional 8 patients. Overall, 19 of the 36 
patients (53%) received an average 13.2-day course (range 6 to 
19 days) of OKT3 before contracting cytomegalovirus_ Of 7 
patients who had cytomegalovirus without prior rejection 6 
(86%) still have functioning allografts, compared to only 13 of 
29 (45%) treated for rejection before cytomegalovirus infection 
occurred. Of the 13 graft losses that occurred after cytomeg. 
alovirus infection (median time 5 weeks) 10 (83%) were due til 
either acute (2) or chronic (8) rejection_ 
Patient and graft survival. The overall I-year actuarial pa-
tient and graft survival rates were 100% and 56%, respectively 
with a mean followup of 12.7 ± 6.2 months. As indica~ 
previously, survival was significantly better for allografts not 
treated for rejection before the onset of invasive cytomegalovi_ 
rus infection (86% versus 45%. p <0_05). Those grafts still 
functioning have a mean serum creatinine of 2.5 mg_/dL (range 
1.2 to 4.6). The I-year actuarial patient and graft survival rates 
for all cadaveric renal transplants (419) performed at our 
institution during the same period were 95% and 80%, respec-
tively. 
DISCL'SSION 
Cytomegalovirus infection is a serious and potentially lethal 
complication in immunocompromised patients. Renal trans-
plant recipients with cytomegalovirus infection have had mor-
tality rates as high as 25% with even higher death rates (up to 
100%) reported for patients with cytomegalovirus pneumoni-
tis. t. l~K [:1 Until recently, the only therapeutic approach for this 
group of patients was to withhold immunosuppression and 
provide supportive care_ Ten years ago the reported incidence 
of overt cytomegalovirus in renal transplant recipients was 40 
to 50%." 14. 10 In this earlier era aggressive use of certain agents, 
such as prophylactic antilymphocyte preparations, was associ-
ated with the development of severe cytomegalovirus infec-
tion. Iii Despite ongoing refinements in immunosuppressive pro-
tocols, the incidence of cytomegalovirus infection in renal 
transplant recipients (cadaveric and living related) has been 
recently reported to be as high as 29%" I A successful approach 
to reducing the incidence of overt cytomegalovirus in renal 
transplant patients has been the use of prophylactic acyclovir.! 1 
However, a finite number of patients will still have cytomeg-
alovirus infection despite acyclovir prophylaxis. The severity 
of subsequent cytomegalovirus is not lessened by prophylactic 
acyclovir in these patients." Attempts to treat established 
cytomegalovirus disease with intravenous acyclovir" as well as 
other antiviral agentst~ ," have been unsuccessfuL 
Ganciclovir selectively inhibits the replication of herpes 
group viruses and is much more potent than acyclovir in vitro.' 
This drug has been used to treat severe cytomegalovirus infec-
tion in patients with the acquired immunodeficiency syndrome 
(AIDS), with initial clinical improvement observed in 73 to 
77%."; However, these patients experience significant relapse 
rates (up to 80%) with up to 100% mortaliti often due to 
disseminated cytomegalovirus_ Early experience with the use 
of ganciclovir for life or sight-threatening cytomegalovirus in-
fection in bone marrow" ~ and solid organ allograft recipi-
ents°- W has been encouraging, with response rates ranging from 
36 to 70%. These patients have responded better to ganciclovir 
than those with Afap~ with less frequent relapse. The use of 
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TABLE 2. Effect of ganciclovir on cytomegalovirus viremia and viruria 
After Ganciclovir Mean 
Days (± Before Ganciclovir 
Initial Culture Neg. Initial Culture Pos. So) to 
Culture Total Neg. Cui· 
Site No. Cui· No.Ob· Remained Became Became Remained ture if Total 
Obtained tures tained 
Neg. Pas. Neg. Pas. Initially 
Pos. (SC) No. (%) No.(%) No.(%) No. (%) Pos. 
Blood 33 17 (52) 22 11 0(0) 0 (0) 11 (100) 0 (0) 7.5 ± 3.6 
Urine 31 19 (61) 16 1 
TABLE :l. I nfiuencc of potential r~Ik faclors on severity of 
cylomegalouiru., infectIOn 
Cytome!(alovirus Severity 
Total No. P Value 
('}O) Mild Moderate Severe Ichi·square) 
~oK E~F :-;0. lOr) NO.ISC) 
Pt. lIj:e lyrs.l: 
Less than 45 23 (64) 18 (78) 4117) 1 (5) 0.52 
45 or more 13 (36) 9 (i0) 2 (lSI :2 (1S) 
ProphylactiC acvclovlr: 
Low dose 281781 21 (751 ;; (IB) 2 (7) 0.85 
Hi!!,n dose 8021 6 (751 1 112.51 1 (12.51 
Days to cytome!(8lovirus 
OMet after transplan· 
tation: 
Lea, than 40 6 (17) :J9 1.:;01 :2 1331 I ilil 0.45 
40-lO0 25 (691 19 1761 41161 ., 181 
100 or more 5041 ~ (100) 0 /01 0 (0) 
Prior reJectIOn: 
Yes 29 (Bll 21 (72) ;; (17) 3 (11) 0.64 
No 7 (19) 6 (86) I (14) 0 (0) 
PriorOKT3: 
Yes 19(53) 14 (74) 4 121) 1 (5) 0.63 
No 17 (471 13 (761 2112) :2 (12) 
Graft loss: 
Yea 17 (47) 11 (64) 311BI 3 (18) 0.15 
No 19 (531 16 (84) 3 Cl6) 0 (0) 
perolo~c status of 
donor IrecipJent:" 
Neg./ne!!'. 4(11) :1 (75) I (25) 0 (0) 
Neg./pos. 5 1141 4 ISO) 11201 0 (01 O.IB 
mMSK/ne~I 161441 11 (69) 3 (19) :2 (12) 
Poa./po •. 9 (25) il (89) 1 (Ill 0 WI 
t • perolo~c Slatus defined by cytome!(alovirus FlAX antibod~D ilgG) titer: less 
':::-negatlve. more than 30-positlve. Serololnc status was unknown in 2 
I!anciclovir for the treatment of cytomegalovirus in renal allo-
g[~aft recipients has been reported for small numbers of patients 
tlt~ .severe disease.' I" Erice et al treated 5 renal transplant 
f!oclplents with severe cytomegalovirus (pneumonitis, retinitis 
~nd gastritis) with improvement observed in 4.' However, al-
ngraft outcome was not reported. In another studv 4 kidney 
',ranlplant recipients with invasive cytomegalovi~s received 
1(8nclc\ovir with a 90% patient survival rate: however. allograft 
:'utcome again was not reported." Harbison et al treated 3 
~;dney transplant recipients with severe cytomegalovirus with 
~ an~al improvement in 2 but only 1 retai~ed graft function. II' 
n~ man noted onlv a 59% clinical response in Ii renal allo-
~fr~ t recipients but· the majority of these patients (12 of 17) 
,ll CYtomegalovirus pneumonitis.' A virological response oc-
t~rred In 470/0 of the patients. Two patients with established 
Kr~etUhze~ cytomegalovirus died despite ganciclovir therapy, 1 
f\1.er multlpl~ courses of the drug. Only 3 of the 6 patients with 
Iii Omegalovlrus pneumonitis responding to ganciclovir re-
at! ned allograft function. The results of these initial reports 
~~t that ganciclovir therapy instituted after the onset of 
tFlyf@~ cytomegalovirus infection may not represent the opti· 
rn Use of this drug.- II' rh~n OUr series ganciclovir was begun in all patients with a l' ~Irn~Ufp of tissue invasive cytomegalovirus infection. regard-1ff11yD~ .the category of disease severity (table 11. Viremia re-Viral ~ 10?% of the patients and viruria in SSt;;. (overall 92% l. J)ltie II eddlng In the urine continued asymptomatically in 2 
. nta but neither had recurrence of invasive disease. Per-
(33) 2 (67) 11 (85) 2 (15) 8.1 ± 4.8 
sistent viruria has been reported in up to 70% of the patients 
treated with ganciclovir," with no adverse impact on clinical 
outcome. Treatment of cytomegalovirus with ganciclovir was 
accomplished with only modest reductions in immunosuppres-
sion (usually azathioprine). The most common side effect ob-
served was leukopenia in 7 patients (19%), followed by throm-
bocytopenia in 2 (5%) and skin rash in 1. Leukopenia and 
thrombocytopenia were transient and did not require cessation 
of ganciclovir therapy. De novo anemia was not observed. In 
patients with a functioning graft, renal function was likewise 
not adversely affected by ganciclovir, with mean serum creati-
nine of 4.1 mg./dl. before and 3.8 mg./dl. after therapy. 
There were no deaths in this series, with an actuarial1-year 
patient survival rate of 100%. All patients had clinical improve-
ment with course 1 of ganciclovir despite concurrent infections 
in 8 (22%). Relapses occurred in 2 patients within 9 weeks of 
the initial course of ganciclovir but both were successfully 
retreated. The overall virological clearance rate of 92% com-
pares favorably with other reported series and usually occurred 
within 1 week of treatment. Although the natural history of 
viral shedding without treatment of cytomegalovirus is not well 
documented, these results suggest that ganciclovir has an an-
tiviral effect in vivo. 
The overall graft survival of 56% in this series is similar 
to that reported previously in cytomegalovirus infected pa· 
tients.:'!11 However. this series differs from these earlier reports 
in several major respects. The definition of cytomegalovirus 
(and therefore the use of ganciclovir) was restricted to patients 
with absolute proof of tissue invasive disease. not merely sero-
conversion and/or viral shedding. All of our patients received 
acyclovir prophylaxis, which has recently been shown to lower 
the incidence (but not the severity) of clinical cytomegalovirus 
in renal transplant recipients. II Thus, our patients acquired 
cytomegalovirus despite acyclovir prophylaxis and. therefore . 
they may be regarded as a high risk group. Whether the patients 
had received low dose or high dose prophylactic acyclovir had 
no influence on the severity of cytomegalovirus infection (p = 
0.85). Of the patients in our series 81 % had been treated for 
rejection before acquiring cytomegalovirus. More than 50% of 
the patients had received OKT3 either as prophylaxis for or 
treatment of rejection. Therefore, this population was already 
at higher risk of graft loss even had cytomegalovirus infectio~ 
not occurred. 
These results have led us to a more aggressive approach in 
patients with proved tissue invasive cytomegalovirus infections. 
We believe that most are able to tolerate ganciclovir with onlv 
a modest (25 to 50%) decrease in the dose of azathioprine. l~ 
our experience cyclosporine can be continued at therapeutic 
doses and steroid doses may be tailored individually. We have 
continued to decrease or withhold immunosuppression in pa-
tients with moderate or severe infections and those with non-
functioning allografts. The efficacy of ganciclovir in the treat· 
ment of tissue invasive cytomegalovirus infection in renal 
transplant recipients would best be studied in a controlled trial. 
Our initial experience with ganciclovir suggests that earlv. 
aggressive treatment of invasive cytomegalovirus infection ca"n 
be accomplished with little or no reduction in immunosuppres-
sion. thus, affording the opportunity for graft salvage and 
optimum patient survival (100% in our series). We observed no 
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progression of cytomegalovirus infection to life-threatening 
disease with this approach. Reservation of ganciclovir treat-
ment only for patients with severe cytomegalovirus has met 
with poor results."-'H The optimum use of this drug will require 
further study and enthusiasm for its use must be tempered by 
recent observations of the emergence of cytomegalovirus strains 
resistant to ganciclovirK~1 However, the limited toxicity and 
prompt, uniform eradication of symptomatic disease observed 
in our series indicate that ganciclovir is a valuable addition to 
the therapeutic armamentarium in the management of cadav-
eric renal transplant recipients with tissue invasive cytomeg-
alovirus infection. 
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